Bell Rock Capital LLC Has $1.59 Million Position in Johnson & Johnson (NYSE:JNJ)

Bell Rock Capital LLC reduced its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 10.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,811 shares of the company’s stock after selling 980 shares during the period. Johnson & Johnson comprises approximately 1.5% of Bell Rock Capital LLC’s investment portfolio, making the stock its 16th largest position. Bell Rock Capital LLC’s holdings in Johnson & Johnson were worth $1,585,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in JNJ. Norges Bank acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $4,172,929,000. BlackRock Inc. boosted its position in Johnson & Johnson by 2.6% during the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after buying an additional 4,982,885 shares during the period. GQG Partners LLC boosted its position in Johnson & Johnson by 1,109.4% during the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock worth $676,375,000 after buying an additional 3,627,424 shares during the period. State Street Corp boosted its position in Johnson & Johnson by 1.8% during the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after buying an additional 2,492,359 shares during the period. Finally, Vaughan Nelson Investment Management L.P. boosted its position in Johnson & Johnson by 5,036.2% during the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 1,227,558 shares of the company’s stock worth $217,560,000 after buying an additional 1,203,658 shares during the period. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $171.11 on Friday. The company has a fifty day moving average of $175.21 and a 200-day moving average of $174.55. The firm has a market capitalization of $449.88 billion, a P/E ratio of 24.91, a P/E/G ratio of 3.32 and a beta of 0.59. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. Johnson & Johnson’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.48 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.64%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on JNJ shares. Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. UBS Group lowered their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. SVB Leerink lowered their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Finally, Morgan Stanley raised their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, July 8th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $189.89.

Insider Activity at Johnson & Johnson

In related news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.